A study by New York City-based NYU Langone Health found a combination of a drug and protein fragment that prevents the growth of blood cancer cells.
The study, presented at the annual meeting of the American Society of Hematology Dec. 9, designed a monobody with a simple protein framework and paired it with a drug called MMAE, which prevents cells from multiplying. The combination stopped abnormal growth in both cell tests and live animals, according to a Dec. 9 system news release.
"Our conjugate improved survival in early tests and has the potential to be important clinically against multiple myeloma," senior author Dafna Bar-Sagi, PhD, senior vice president, vice dean for science, and chief scientific officer at NYU Langone, said in the release.